Cinnamon and Derivatives as Modulators of Toll-like Receptors
Georges Maalouly, Marc Gemayel, Roy Khoury, Nassim Fares · 2026
Read Cinnamon and Derivatives as Modulators of Toll-like Receptors by Georges Maalouly, Marc Gemayel, Roy Khoury, Nassim Fares (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13607542.txt.
Introduction
Georges Maalouly, Marc Gemayel, Roy Khoury, and Nassim Fares published a review in twenty twenty-six on cinnamon compounds as adjusters of Toll-like receptors, the immune system's front-line sensors. Those receptors also entangle with oxidative stress, so calming them could help many diseases. Cinnamon's main active, cinnamaldehyde, is the leading candidate.
Experiments and docking studies show cinnamaldehyde gripping receptors TLR2 and TLR4 directly, blocking the pairings they need to fire. Early evidence also hints at action on TLR7. Because the plain compound is poorly absorbed, researchers have built nanoformulations and semi-synthetic versions to deliver it better. The review weighs strong laboratory plausibility against still-thin clinical proof.
Catalog record
| CREATOR | Georges Maalouly, Marc Gemayel, Roy Khoury, Nassim Fares |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Cinnamon and Derivatives as Modulators of Toll-like Receptors Authors: Georges Maalouly, Marc Gemayel, Roy Khoury, Nassim Fares Published: 2026 ABSTRACT Toll-like receptors (TLRs) are critical components of the innate immune system, acting as pattern recognition receptors and interacting with oxidative stress. TLR2, TLR4, and TLR7 play distinct yet overlapping roles in immune regulation, contributing to both physiological processes and disease progression. Therefore, modulation of TLR signaling pathways represents a promising therapeutic strategy for a wide range of diseases. Natural antioxidants have attracted considerable interest as modulators of TLRs, with cinnamon-derived phytochemicals, particularly cinnamaldehyde, emerging as promising candidates for the treatment of TLR-mediated diseases. Experimental evidence, supported by molecular docking studies, demonstrates that cinnamaldehyde directly interacts with TLR2 and TLR4. Specifically, it inhibits ligand-induced heterodimerization of TLR2 with TLR1 and TLR6, while binding to MD-2 to prevent TLR4 oligomerization and subsequent receptor activation. Furthermore, emerging evidence suggests that cinnamaldehyde may also interact with TLR7 and suppress its downstream signaling. To improve the pharmacokinetic properties, bioavailability, and targeted delivery of cinnamon-derived compounds, nanoformulations and semi-synthetic derivatives have been developed and have shown potential to modulate TLR signaling pathways. However, despite the strong biological plausibility and experimental evidence supporting the parent cinnamaldehyde scaffold as a direct TLR modulator, direct interactions between TLRs and these advanced formulations or semi-synthetic derivatives remain insufficiently documented. 1. Introduction Toll-like receptors (TLRs) are critical components of the innate immune system, acting as pattern recognition receptors (PRRs) that detect pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). PAMPs are conserved molecular structures (like peptidoglycan and lipopolysaccharide) found in groups of pathogens but are absent in host cells [1], while DAMPs are endogenous molecules (like proteins, nucleic acids or metabolites) that are released or exposed by cells undergoing stress, injury, or death [2]. Several TLRs, such asTLR2, TLR4, and TLR7, are integral to both physiological and pathological processes, with distinct and overlapping roles in immune regulation, inflammation, and disease progression [3,4]. Targeting TLR signaling pathways has emerged as a promising therapeutic strategy for a wide range of diseases, including sepsis, autoimmune disorders, cancer, and malaria, with both agonists and antagonists under investigation to either dampen pathological inflammation or enhance protective immune responses [5,6,7,8]. TLRs are redox-sensitive receptors [9]. Natural antioxidants have emerged as potential modulators of TLR signaling pathways owing to their ability to target key molecules, including inhibition of LPS–TLR4 interactions, disruption of TLR2/TLR1 heterodimerization, and suppression of downstream inflammatory cascades [8,9,10,11]. Among these, cinnamon-derived compounds, particularly cinnamaldehyde, have attracted considerable attention for their anti-inflammatory properties in TLR-mediated disorders, including diabetes, inflammatory bowel disease, and periodontitis [12,13,14]. Despite these promising pharmacological activities, the clinical translation of cinnamon-derived compounds remains constrained by poor aqueous solubility, limited chemical stability, and potential toxicity [10,15,16]. These limitations have been behind the development of nanoformulations, nanoemulsions, biopolymer conjugates and semi-synthetic derivatives designed to enhance bioavailability, stability, and therapeutic efficacy [3,17] and may benefit from pharmacophore modeling [18]. However, the mechanisms by which these advanced formulations modulate TLR signaling, and whether they retain the direct receptor-targeting properties of the parent compounds, remain non-elucidated. This narrative review aims to review the role of cinnamon natural compounds, antioxidant activity mechanisms, and modern formulations and derivatives as potential modulators of TLRs. 2. TLRs in Physiology and Pathology 2.1. Subtypes and Cellular Distribution TLRs are a family of PRRs that play a pivotal role in the innate immune system by recognizing PAMPs and DAMPs. Their discovery as a Drosophila fly gene involved in establishing the dorsal–ventral axis during its development, and subsequently as an antimicrobial response mediator, led to a deeper understanding of host defense and immune activation [10,11]. These receptors initiate immune responses by detecting microbial components such as lipids, nucleic acids, and proteins, as well as endogenous molecules released during tissue damage [12,13,14]. TLRs act as a bridge between innate and adaptive immunity, promoting the production of inflammatory cytokines, upregulation of co-stimulatory molecules, and functional maturation of antigen-presenting cells [14,15]. TLRs are transmembrane proteins with an extracellular domain containing leucine-rich repeats (LRRs) for ligand recognition and a cytoplasmic Toll/IL-1 receptor (TIR) domain for signal transduction. Ten types are documented in humans [10]. Ligand binding induces dimerization of TLRs, bringing their TIR domains into proximity, which is essential for downstream signaling [3,16]. TLRs are categorized into two subfamilies based on their localization: cell surface TLRs (e.g., TLR2, TLR4) and endosomal TLRs (e.g., TLR7) [3]. This distribution on the cell surface and on endosomal membranes gives TLRs the ability to recognize antigens in different cellular locations [10]. TLRs are predominantly expressed on immune cells such as macrophages, dendritic cells, and B cells, where they play a critical role in pathogen recognition and immune activation [17,19]. Additionally, TLRs are also expressed on non-immune cells, including epithelial and renal cells, where they contribute to tissue repair, inflammation, and responses to injury [20,21]. 2.2. TLR2, 4 and 7 Ligands and Signaling Pathways TLRs recognize microbial ligands, resulting in the activation of signaling pathways and transcription factors and inducing the expression of genes whose products are necessary for inflammatory and antiviral responses [10]. PAMPs from Gram-positive bacteria, such as peptidoglycan and bacterial lipoproteins, activate TLR2 [22]. TLR2 also responds to DAMPs released from necrotic cells or tissue damage [23]. TLR2 forms heterodimers with TLR1 or TLR6 to recognize these ligands, primarily signaling through the MyD88 pathway [16]. TLR4 recognizes lipopolysaccharides (LPSs) and signals through both MyD88 and TRIF pathways, making it multifaceted in immune responses; LPS-binding protein (LBP) and CD14 are essential for transferring LPSs to the TLR4/MD-2 complex, enabling sensitive and regulated immune responses to Gram-negative bacteria [11,16]. MD2 (myeloid differentiation protein 2) is a critical accessory protein for Toll-like receptor 4 (TLR4), playing essential roles in both the structural assembly and functional activation of the TLR4 complex, particularly in response to LPS. It is a secreted extracellular glycoprotein that binds directly to the extracellular domain of TLR4, forming the TLR4/MD2 complex necessary for LPS recognition and signal transduction [24]. MD2 contains a unique hydrophobic cavity that specifically binds the lipid A portion of LPS, facilitating the recognition of Gram-negative bacterial components [25]. MD2’s structure includes several cysteine residues forming disulfide-linked oligomers, which are important for its stability and function [26]. Upon LPS binding, the TLR4-MD2-LPS complex undergoes dimerization, which is required for downstream signaling [27]. Other ligands of TLR4 are endogenous molecules (like HMGB1, S100A8/9, heme, and fetuin-A) [28]. TLR7 is activated by single-stranded RNA (ssRNA), common in viral infections [29], and by endogenous RNA molecules released during cellular stress or damage [29]. The MyD88-dependent pathway is the primary signaling mechanism for most TLRs, including TLR4, TLR2, and TLR7. Upon ligand binding, TLRs recruit the adaptor protein MyD88, leading to the activation of transcription factors such as NFκB and AP-1. This pathway drives the production of pro-inflammatory cytokines and type I interferons, which are critical for pathogen defense and immune activation [3,12,29]. TLR4 uniquely utilizes both MyD88-dependent and MyD88-independent pathways. The TRIF-dependent pathway is activated when TLR4 is localized to endosomes, leading to the production of type I interferons via IRF3 activation. This pathway is crucial for antiviral responses and is also utilized by endosomal TLRs like TLR7 [3,12,29] (Table 1). 2.3. TLR in Pathology and Modulation by Cinnamon Derivative